Hyundai Bioscience Co., Ltd. (KOSDAQ:A048410), CnPharm Co., Ltd. and Yeonjin Kim agreed to acquire 34.91% stake in ADM Korea Inc. (KOSDAQ:A187660) from Mobiis Co., Ltd. (KOSDAQ:A250060) for KRW 31 billion on March 11, 2024. As of May 16, 2024, the agreement was revised and under the revised terms Hyundai Bioscience will now acquire 30.33% stake, CnPharm will acquire 2.89% stake and Yeonjin Kim will acquire 1.69% stake in ADM Korea. Transaction is expected to May 20, 2024.